Pathological complete response predictor of favorable breast cancer outcome

April 2, 2014
Pathological complete response predictor of favorable breast cancer outcome

Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer.

Professor Hervé Bonnefoi of the Institut Bergonié Comprehensive Cancer Centre in Bordeaux and coordinator of this study says, "An analysis such as the EORTC's was needed to consider heterogeneity. Until recently, a link between pathological complete response and excellent prognosis had only been shown for some specific subtypes of breast cancer, e.g. triple negative and HER2-positive breast cancers, albeit with conflicting results. We wanted to see if the prognostic implications of pathological complete response, TP53 status, and the treatment administered (taxane or non-taxane) differed among breast cancer subtypes. We performed a landmark and two-step approach multivariate analyses to address these questions."

Patients in the intergroup EORTC 10994/BIG 1-00 phase III trial were randomized to receive either six cycles of anthracycline-based chemotherapy (non-taxane) or three cycles of docetaxel followed by three cycles of eprirubicin/docetaxel (taxane). Researchers used a landmark approach and a two-step multivariate analysis to study the potential effects of three interactions: breast cancer subtype and pathological complete response; breast cancer subtype and TP53 status; breast cancer subtype and treatment arm (i.e., taxane or non-taxane).

A patient was determined to have pathological complete response when no evidence was found of residual invasive cancer (or very few scattered tumor cells only) in the primary tumor and lymph nodes. According to this definition, pathological complete response was observed in 18% of the patients in this trial for whom sufficient data was available (1212 of the 1856 patients randomized).

In the univariate analyses there is no heterogeneity between the Hazard Ratios for pathological complete response in our study across the different subtypes. The prognostic effect of pathological complete response on event-free survival did not differ between breast cancer subtypes in a two-step multivariate analysis and was an independent predictor for better event-free survival (Hazard ratio (HR) = 0.40, P < 0.001 in favor of pathological complete response), distant metastasis-free survival (HR = 0.32, P < 0.001), and overall survival (HR = 0.32, P < 0.001). The findings have been confirmed in the recent FDA meta-analysis.

The treatment administered, i.e., taxane or non-taxane, was an independent predictor only for event-free survival and favored treatment with taxane (HR = 0.73, P = 0.004 ). The interaction between breast cancer subtype and TP53 only approached statistical significance for event-free (P = 0.1).

Related Stories

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012

(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Exciting results from cancer immunoagent study

July 20, 2015

(Medical Xpress)—Cancer therapies have improved incrementally over the years, but cancer treatment largely remains analogous to forest fire suppression, in which the spread of fire is contained with deliberate controlled ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.